Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Our team works collaboratively and relentlessly to advance our therapies; all with the goal of improving the lives of patients, their families, and their caregivers.
The Radius portfolio consists of commercial and clinical development assets, that include early to late-stage drug candidates.
In the area of bone health, we are dedicated to serving those patients suffering from bone loss such as the 8.9 million osteoporotic fractures that occur annually worldwide according to the International Osteoporosis Foundation. In 2017, we launched our first commercial product in the U.S. for post-menopausal women with osteoporosis at high risk for fracture and currently have two late-stage clinical trials in progress with read-outs expected in late 2021.
Our orphan business group is centered around the clinical development of our investigational synthetic cannabidiol oral solution (RAD011), which has potential utilization in multiple rare disease areas. We are initially focused on the treatment of Prader-Willi syndrome (“PWS”), which is a complex genetic disorder with clinical manifestations in the endocrine and neurological systems. The disease primarily impacts the pediatric patient community and continues into adulthood. Our team is driven by the needs of those suffering from rare diseases and seeks to expand its initiatives to other neuroscience areas.
In July 2020, Radius entered into an exclusive global license agreement with Menarini Group for the development and commercialization of elacestrant, an investigative oral selective estrogen receptor degrader (SERD) currently being evaluated in a Phase 3 study (EMERALD) as a hormonal treatment for postmenopausal breast cancer.
At Radius, we are motivated by making a difference: for our employees, our partners, and – most importantly – the lives of patients, their families, and their caregivers.